MonumenTAL-1: Efficacy and Safety Data
Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.
EP: 1.Significance of GPRC5D as a Target for R/R MM
EP: 2.Long-Term Follow-Up of MonumenTAL-1
Now Viewing
EP: 3.MonumenTAL-1: Efficacy and Safety Data
EP: 4.Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma
EP: 5.Overview of MonumenTAL-2 and MonumenTAL-3
EP: 6.Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3
EP: 7.Exploring GPRC5D as an Important Target for Multiple Myeloma
EP: 8.Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
EP: 9.Implications of Combination Regimens for R/R MM
EP: 10.Overview of Recent Updates in Bispecific Therapy in R/R MM
EP: 11.Impact of T-cell Affinity in Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- How do the overall response rates (ORRs) in both naive and previously exposed patients impact the potential use of this treatment in clinical practice?
- Please comment on the safety results seen in the LTFU MonumenTAL-1 data.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
